
    
      Patients receive hLL1-DOX at one of 4 dose levels administered on Days 1, 4, 8 and 11 of
      21-day treatment cycles which are continued in the absence of progression or unacceptable
      toxicity up to a total of 8 cycles. After treatment, follow-up will be done at 4, 8 and 12
      weeks post-treatment and will continue to be done every 3 months for up to 2 years.
    
  